Compare NNN & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNN | BLCO |
|---|---|---|
| Founded | 1984 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Ophthalmic Goods |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 7.1B |
| IPO Year | 1995 | 2022 |
| Metric | NNN | BLCO |
|---|---|---|
| Price | $41.31 | $21.35 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 18 | 15 |
| Target Price | ★ $45.03 | $21.71 |
| AVG Volume (30 Days) | ★ 2.8M | 972.4K |
| Earning Date | 11-04-2026 | 10-28-2026 |
| Dividend Yield | ★ 5.94% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.58 | N/A |
| Revenue | $926,213,000.00 | ★ $5,101,000,000.00 |
| Revenue This Year | $6.19 | $7.83 |
| Revenue Next Year | $5.33 | $5.90 |
| P/E Ratio | $26.41 | ★ N/A |
| Revenue Growth | ★ 6.55 | 6.47 |
| 52 Week Low | $38.90 | $14.44 |
| 52 Week High | $50.00 | $21.36 |
| Indicator | NNN | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 47.61 | 74.45 |
| Support Level | $40.50 | $15.30 |
| Resistance Level | $45.52 | $21.36 |
| Average True Range (ATR) | 0.76 | 0.72 |
| MACD | 0.07 | 0.23 |
| Stochastic Oscillator | 40.20 | 98.25 |
NNN REIT Inc is a real estate investment trust that acquires, owns, invests in, and develops high-quality properties mainly leased under long-term net leases with minimal capital expenditure requirements. The company focuses mainly on retail properties, with a portfolio including convenience stores, automotive service properties, restaurants, theatres, entertainment venues, dealerships, and other retail-related assets. Primary business objectives emphasize retail properties, and it may invest in a wide variety of property and tenant types, leases, mortgages, loans secured by personal property, loans secured by partnership or membership interests, and securities of other REITs or other issuers.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes brands like Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, and surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xiidra and Miebo that treat various eye complications.